Guangdong Pulse Medical Technology Co., Ltd. (referred to as "Pulse Medical") has completed its Series C financing, which is jointly invested by Weilai Capital and Yuecai Biomedical Fund, with Xingyuan Zhitong serving as the exclusive financial advisor.
Pulse Medical was established in Zhuhai in 2014, focusing on the research and production of cardiovascular medical devices. The company adopts a deep "medical engineering integration" research and development model, fully leveraging the special role of senior clinical experts in deep understanding of patient needs, which is conducive to overcoming the shortcomings of existing products, absorbing the advantages of existing products, significantly reducing trial and error costs and time, and creatively designing new products with global leading level.
The company has developed a series of structural heart disease intervention devices and created multiple domestic firsts: the world's only left atrial appendage occluder with a dual body plug structure is about to be commercialized for sale; The world's first perforated single rivet double disc structure patent foramen ovale (PFO) occluder is about to enter clinical trials. At the same time, the company is actively developing multiple innovative cardiovascular medical devices, committed to building a leading high-end medical device innovation platform for structural heart disease in China.
The Lefear left atrial appendage occluder of the company was selected as one of the "Six Excellent Chinese Original Research" cardiovascular medical devices at the 2020 China Interventional Cardiology Conference (CIT-2020) and recommended to participate in the 2020 European Cardiovascular Intervention Conference (EuroPCR 2020). The product development team gave a special presentation at the EuroPCR 2020 conference, announcing the latest clinical research data of Lefear left atrial appendage occluder to the world, and received high praise from peer experts worldwide. On June 30, 2020, the "Study Strong Country" learning platform of the Propaganda Department of the Communist Party of China Central Committee reported on the research progress and safe and effective clinical trial data of the Lefear left atrial appendage occluder for pulse medicine presented by the R&D team at the European Cardiovascular Intervention Conference (EuroPCR 2020).
Since its establishment, the company has been closely cooperating with senior experts in the cardiovascular field from multiple top tier tertiary hospitals, practicing a deep "medical engineering integration" research and development model. A deep analysis of the actual effects of similar products in Europe and America in clinical trials and clinical use in East Asia is an important source of information and data for the development of domestic high-end cardiovascular medical devices. Innovation on the shoulders of giants is one of the shortcuts to surpassing them.
The deep cooperation between engineering and technical experts in the Pulse Medical R&D department and senior clinical experts can greatly shorten the trial and error process, reduce R&D costs, improve R&D speed, and ultimately develop high-end medical devices with world leading levels. The physiological structure of East Asians is different from that of Europeans and Americans, and there are significant differences in some aspects. Physical structure is an important factor in the functioning of medical devices, so the development of medical devices for East Asians must be based on the physiological structure of East Asians!
Atrial fibrillation is the most common arrhythmia, with over 13 million atrial fibrillation patients in China (of which non valvular atrial fibrillation accounts for about 65%), and it is increasing year by year with the trend of population aging. Thrombosis caused by atrial fibrillation often leads to serious consequences. The risk of ischemic stroke in atrial fibrillation patients is more than 5 times that of normal individuals, and over 95% of thrombosis in non valvular atrial fibrillation patients comes from the left atrial appendage. Traditional anticoagulant therapy has significant side effects on the human body, and left atrial appendage occlusion (LAAC) is a modern new method to replace traditional anticoagulant therapy for thrombosis in non valvular atrial fibrillation patients.
Patent foramen ovale (PFO) is a structural heart disease that cannot be detected during prenatal examinations in pregnant women. The foramen ovale usually closes in the first year after birth in infants. If the foramen ovale still does not close after the age of 3, it becomes "patent foramen ovale (PFO)". The clinical symptoms of PFO include dizziness, headache, syncope, cerebral ischemia (TIA), cerebral infarction, and other symptoms. Anatomical statistics show that the incidence of patent foramen ovale (PFO) is 30% in individuals aged 1 to 29, 25% in individuals aged 30 to 79, and 20.2% in those aged 80 and above. With the advancement of PFO closure surgery and the increasing awareness of the hazards of PFO among patients, the demand is growing day by day.
Pulse Medical has established a proprietary research and production base in Zhuhai High tech Industrial Development Zone, which is equipped with an annual production line for 30000 sets of left atrial appendage occluders and 30000 sets of PFO occluders. The base can support the company's annual net profit scale of over 450 million yuan.
Pulse Medical R&D and Production Base
Since its establishment, Pulse Medical has received strong support from well-known medical funds such as Chende Capital, Shanlan Capital, Weilai Capital, and CMB Zhiyuan, as well as support from local venture capital funds in Zhuhai. It has now grown into an influential structural high-end medical device research and development platform for heart disease in the Greater Bay Area. With the support of Weilai Capital and Bank of China Guangdong Finance, Pulse Medical will step up to a higher level at a faster pace!
Chairman Ruan Chengmin, founder of Pulse Medical, said, "We are very grateful for the love of new and old shareholders such as Weilai Capital and Zhongyin Yuecai for Pulse Medical, as well as the professional services of Xingyuan Zhitong. Since we started our business, we have experienced many difficulties, and with the help of institutional investors, Pulse Medical has achieved steady growth year by year. We will continue to deepen the 'medical engineering integration' research and development model, develop high-end products with huge clinical demand potential, and provide higher quality cardiovascular medical equipment products for East Asians, including China
Zhao Yang, Managing Partner of Weilai Capital, said, "Pulse Medical's medical engineering integrated research and development model has sustained competitive advantages. Weilai Capital is optimistic about Pulse Medical's platform based research and development capabilities, and will continue to provide support in terms of funding, research and development, and channels in the future
Meng Shengrong, Director of Zhongyin Yuecai Investment, said, "Pulse Medical has developed multiple innovative products for structural heart disease using a combination of medical and engineering research and development models. We are optimistic about the field of structural heart disease and recognize Pulse Medical's product development capabilities. Yuecai Biomedical Fund hopes to work with the company to provide more high-end cardiovascular equipment products for patients, and will continue to focus on outstanding innovation and entrepreneurship teams in the field of big health to promote the successful industrialization of innovative products in the biopharmaceutical health industry
Regarding Weilai Capital
Weilai Capital was established in March 2018 and is a leading comprehensive industrial investment fund in China. Its investment areas cover medical, health, and technology fields, with a fund management scale of 1.5 billion yuan and asset management scale of nearly 8 billion yuan. In the medical field, Weilai Capital has successively laid out tracks such as pharmaceutical new retail, assisted reproduction, cardiac intervention, early cancer screening, and artificial pancreas.
About Zhongyin Yuecai
Zhongyin Yuecai Equity Investment Fund Management (Guangdong) Co., Ltd. is a joint venture established by Guangdong Yuecai Investment Holdings Co., Ltd. and Zhongyin Group Investment Co., Ltd. It mainly focuses on five investment directions: healthcare, new energy, advanced manufacturing, consumption, and infrastructure. The fund has a cumulative management scale of over 40 billion yuan.
Regarding Xingyuan Zhitong
StartPoint Advisors is a financial advisory firm specializing in the healthcare industry. The company was established in 2020, and the team comes from well-known institutions in the industry with rich professional experience. Currently, we have offices in Beijing, Suzhou, and Guangzhou. Since its establishment, the company has achieved full coverage in the medical and health field, and has a good professional reputation and word-of-mouth in the industry. It is currently one of the most representative emerging investment banks in the domestic medical and health field.